Loading…
← CockpitCompetitor Analysis › ODTX Odyssey Therapeutics, Inc.Open in the cockpit ↗

Odyssey Therapeutics, Inc.ODTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum neutral 46
Mkt cap
$912M
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$6.46M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-193.5 pp
WACC 19.7%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$18.98
1D-2.0%
1W-9.6%
1M-0.1%
3M-23.1%
6M+11.9%
YTDn/a
1Yn/a
ATR %8.5%
52w lowhigh34.7% off high

What Odyssey Therapeutics does

No business profile yet.

Odyssey Therapeutics at a glance

Size Odyssey Therapeutics (ODTX) is a United States Health Care company (Biotechnology) with a market value of $912M, the 2287th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.98 on 18 Nov 2026.

Performance Over six months the shares gained 11.9%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 33.5% over the last twelve months (peer median +2.0%); the operating margin is -5,415.2% (peer median -21.2%).

Valuation It trades at 204.9× enterprise value to sales against a peer median of 5.6× (2nd most expensive of 18).

Capital Return on invested capital runs 193.5 points below its cost of capital (19.7% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026ODTX 107Peer median 83
Six months, rebased to 100: Odyssey Therapeutics against the median of its 20 peers (local-currency closes).

Odyssey Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a$2.98M$4.47M$1.04M$0
Revenue growth—-33%+331%——
Gross profitn/a-$1.94M-$721,000-$3.87M-$2.76M
EBITDAn/a-$156M-$130M-$129M-$120M
Net incomen/a-$149M-$129M-$126M-$125M
Free cash flown/a-$131M-$118M-$118M-$113M
Capital expendituren/a$1.23M$764,000$5.06M$13.0M
Total debt$23.5M$27.1M$31.0M$34.4M$40.9M

Quarterly statements and history in the cockpit →

Odyssey Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%68825330084160019521604587VSTMOXB688276SGPINBXMGTXANRO3004829606688526JBIOGLUESNDX9887ODTX6-month return →1-month return →
Up and to the right = strong over both horizons. Odyssey Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×200×400×688253300841VSTMINBXMGTXSNDXODTXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Odyssey Therapeutics is the large dot.

Odyssey Therapeutics competitors and peer comparison

How Odyssey Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Odyssey Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureODTXPeer medianRank in peer set
1-month return-0.1%-9.0%7th highest of 21
6-month return+11.9%-17.5%4th highest of 21
Distance from 52-week high-34.7%-41.8%5th highest of 21
Revenue growth (TTM)-33.5%+2.0%2nd lowest of 17
Operating margin-5,415.2%-21.2%2nd lowest of 18
EV / Sales204.9×5.6×2nd most expensive of 18
ROIC minus cost of capital-193.5 pp-8.9 pplowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a

Questions

Which companies are Odyssey Therapeutics's closest peers?
The cockpit's peer set: Innovita Biological Technology (688253.SS), Chengdu Kanghua Biological Products Co. Td Class 1 (300841.SZ), China Animal Husbandry Industry (600195.SS), GNI (2160.T), Peptidream (4587.T), Verastem (VSTM), Oxford BioMedica (OXB.L), Changchun BCHT Biotechnology (688276.SS).
Is Odyssey Therapeutics expensive compared with its peers?
On ev / sales it trades at 204.9× against a peer median of 5.6×, 2nd most expensive of 18 in its peer set.
How has Odyssey Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +11.9% against -17.5% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.